Showing 2521-2530 of 6036 results for "".
- New Study Unveils How Immune Cells Defend the Eye Against Inflammationhttps://modernod.com/news/new-study-unveils-how-immune-cells-defend-the-eye-against-inflammation/2482470/In a new study, researchers led by Sue Menko, PhD, of Thomas Jefferson University, have revealed how immune cells play a critical role in resolving inflammation on the surface of the eye’s lens. Published in The American Journal of
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the 
- Nicox and Glaukos Sign Global Licensing Deal for Glaucoma Drug Candidatehttps://modernod.com/news/nicox-and-glaukos-sign-global-licensing-deal-for-glaucoma-drug-candidate/2482451/Nicox has entered into an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. The collaboration aims to accelerate research and development efforts for glaucoma and other serious ophth
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- Ripple Therapeutics Partners with AbbVie to Develop Intracameral Implant for Glaucomahttps://modernod.com/news/ripple-therapeutics-partners-with-abbvie-to-develop-intracameral-implant-for-glaucoma/2482444/Ripple Therapeutics announced a collaboration and option-to-license agreement with AbbVie to advance the development of RTC-620, a fully biodegradable, sustained-release intracameral implant designed to reduce IOP in patients suffering from open-angle glaucoma (OAG) or ocular hypertensi
- Atsena Therapeutics Granted FDA Orphan Drug Designation for Gene Therapy Targeting XLRShttps://modernod.com/news/atsena-therapeutics-granted-fda-orphan-drug-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482443/The FDA has granted Orphan Drug Designation to Atsena Therapeutics' product candidate, ATSN-201, which is designed for the treatment of X-linked retinoschisis (XLRS). This gene therapy utilizes the company’s AAV.SPR capsid technology, which enables targeted gene expression in the p
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.
- Opthea Announces Executive Leadership Changes and Senior Hireshttps://modernod.com/news/opthea-announces-executive-leadership-changes-and-senior-hires/2482429/Opthea announced several executive leadership changes aimed at bolstering the company’s commercial and clinical expertise as it prepares for the anticipated 2025 topline data readout of phase 3 trials for its lead candidate, sozinibercept, in wet AMD. Daniel Geffken, Co-Founder an
- Oculus Debuts Dual Testing Functionality on Easyfield VR for Enhanced Visual Field Assessmenthttps://modernod.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/Oculus has announced the debut of dual testing functionality on its Oculus Easyfield VR, which allows for both Frequency Doubling Perimetry (FDP) and Standard Automated Perimetry (SAP). The integration of Frequency Doubling Perimetry into the Easyfield VR allows for the potent
- Rayner Launches First AI-Designed Spiral IOL, the RayOne Galaxyhttps://modernod.com/news/rayner-announces-launch-of-rayone-galaxy-first-ai-designed-spiral-iol/2482411/Rayner announced its plans to launch the RayOne Galaxy and Galaxy Toric, which the company is calling the world’s first IOL designed with the aid of artificial intelligence. The IOLs will be unveiled at the European Society of Cataract and Refractive Surgeons (